Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 332 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Protective HPV Vaccine-Induced Antibody Titres Can Be Detected Up To 12... June 1, 2021 Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC... October 3, 2024 Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with... March 31, 2023 Making Cancer Clinical Trials Available to More Patients March 7, 2019 Load more HOT NEWS Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors One Million Masks Donated! But GreaterGood Will Continue to Help Where... From smouldering ash to a gleaming temple for cancer research: The... Withdrawal of the Application to Change the EMA Marketing Authorisation for...
